<DOC>
	<DOCNO>NCT01796665</DOCNO>
	<brief_summary>The objective study evaluate efficacy safety Perrigo 's test formulation Clindamycin Phosphate Benzoyl Peroxide Topical Gel 1.2 % /2.5 % compare already market formulation , Acanya gel patient acne vulgaris .</brief_summary>
	<brief_title>A Study Compare Clindamycin Phosphate Benzoyl Peroxide Topical Gel 1.2 % /2.5 % Acanya® Topical Gel Treatment Acne Vulgaris</brief_title>
	<detailed_description />
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Clindamycin</mesh_term>
	<mesh_term>Clindamycin palmitate</mesh_term>
	<mesh_term>Clindamycin phosphate</mesh_term>
	<mesh_term>Benzoyl Peroxide</mesh_term>
	<criteria>1 . Subject and/or parent legally authorize representative must sign Institutional Review Board ( IRB ) approve write informed consent/assent . 2 . Male female , 12 40 year age , inclusive . 3 . Definite clinical diagnosis facial acne vulgaris inflammatory lesion ( papule pustule ) count 20 50 noninflammatory ( open close comedo ) lesion count 25 100 2 nodulocystic lesion ( i.e. , nodule cyst ) include present nose . 4 . Baseline Investigator 's Global Assessment Score 3 ( moderate severity ) 4 ( severe ) severity scale 0 4 . 5 . Willing able understand comply requirement study , apply medication instruct , refrain use topical acne medication topical antibiotic 12week treatment period , return require treatment period visit , comply therapy prohibition , able complete study . 6 . In general good health free clinically significant disease , acne vulgaris , might interfere study evaluation . 7 . Females childbearing potential ( exclude woman surgically sterilize post menopausal least 2 year ) , addition negative urine pregnancy test , must willing use acceptable form birth control study . For purpose study , follow consider acceptable method birth control : Oral Contraceptives , Contraceptive patch , Contraceptive Injection ( DepoProvera ) , Contraceptive Implant ( Implanon ) , Vaginal Contraceptive ( NuvaRing ) , IUD , hormonal IUD ( Mirena ) ; doublebarrier method ( e.g . condom spermicide ) abstinence document second acceptable method birth control subject become sexually active . A sterile sexual partner consider adequate form birth control . Subjects enter trial hormonal contraceptive must method least 3 month ( 90 day ) prior trial continue method duration trial . Subjects use hormonal contraception stop must stop less 3 month ( 90 day ) prior baseline . 1 . Pregnant , breast feeding , plan pregnancy within study participation period . 2 . More 2 facial nodulocystic lesion ( i.e . nodule cyst ) . 3 . Acne conglobata , acne fulminans , secondary acne ( chloracne , druginduced acne , etc. ) . 4 . Active cystic acne Polycystic Ovarian Syndrome . 5 . History presence Crohn 's disease , ulcerative colitis , regional enteritis , antibioticassociated colitis . 6 . Use neuromuscular block agent ( nondepolarizing agent depolarize agent ) 7 . Any facial skin condition might interfere acne vulgaris diagnosis and/or assessment ( e.g. , face : rosacea , dermatitis , psoriasis , squamous cell carcinoma , eczema , acneform eruption cause medication , steroid acne , steroid folliculitis , bacterial folliculitis ) . 8 . Excessive facial hair ( e.g . beard , sideburn , moustache , etc . ) would interfere diagnosis assessment acne vulgaris . 9 . History unresponsiveness topical Clindamycin Phosphate and/or benzoyl peroxide therapy . 10 . Use systemic Clindamycin product 4 week prior baseline throughout study . 11 . History hypersensitivity allergy Clindamycin Phosphate , benzoyl peroxide and/or ingredient study medication . 12 . Use within 6 month prior baseline study oral retinoids ( e.g . Accutane® ) therapeutic vitamin A supplement great 10,000 units/day ( multivitamin allow ) . 13 . Use within 30 day prior baseline study therapeutic vitamin D supplement ( daily multivitamin total 800IU Vitamin D allow ) . 14 . Use medication know exacerbate acne ( Vitamin B12 , lithium , corticosteroid ; Vitamin B12 , etc part multivitamin regimen allow ) . 15 . Start change dose hormonal treatment ( oral , implanted , topical contraceptive androgen ) 3 month prior baseline throughout study . Use therapy must remain constant study . 16 . Use medicate makeup throughout study significant change use consumer product within 30 day study entry throughout study ( study supply cleanser lotion ) . 17 . Use within 30 day prior baseline study 1 ) systemic steroids* , 2 ) systemic ( e.g. , oral injectable ) antibiotic , 3 ) systemic treatment acne vulgaris ( oral retinoids require 6month washout ) , 4 ) systemic antiinflammatory immunosuppressive agents** . ( *Intranasal inhale corticosteroid require washout may use throughout study stable standard dose . ) **Subjects may use Acetaminophen pain relief , need throughout study ) . 18 . Use within 14 day prior baseline study 1 ) topical steroid , 2 ) topical retinoids , 3 ) topical antiacne medication ( e.g . Benzoyl peroxide , retinoids , azelaic acid , αhydroxy/glycolic acid , Clindamycin , etc . ) include OTC preparation 4 ) benzoyl peroxide , 5 ) topical antiinflammatory agent , 6 ) topical antibiotic . 19 . Use face within 30 day prior baseline study 1 ) cryodestruction chemodestruction , 2 ) dermabrasion , 3 ) photodynamic therapy , 4 ) acne surgery , 5 ) intralesional steroid , 6 ) xray therapy . 20 . Use medicate cleanser ( e.g . benzoyl peroxide , salicylic acid , sulfur triclosan ) within 2 week study start throughout study . 21 . Subject consumes excessive alcohol , abuse drug , condition could compromise subject 's ability comply study requirement . 22 . Use Spironolactone 4 week prior baseline visit throughout study period prohibit . 23 . Use Antipruritics , include antihistamine within 24 hour study visit ( Visit 1 Visit 4 ) . 24 . Participation clinical study involve investigational product device 4 week prior study entry throughout study . 25 . Previous enrollment current study . 26 . Use tanning booth , sun lamp , sunbathe excessive exposure sun 1 week prior enrollment throughout study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>